Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Tuesday, March 31, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: AbbVie Inc. has updated its guidance for the first quarter and full year of 2026, factoring in acquired IPR D and milestones expense. The adjusted diluted EPS for Q1 2026 is projected between $2.56 and $2.60, reflecting a significant expense of $744 million. For the full year, the guidance indicates an adjusted diluted EPS range of $13.96 to $14.16. Notably, the company's guidance excludes any potential expenses incurred after the first quarter, underscoring the uncertainty of future financial impacts.
Price reaction · baseline $213.12 (2026-03-30 close) · hit after-hours · 1 other ABBV headline(s) in the window, move may be shared
day 0 close · peak
+2.1%
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie has provided updated guidance for Q1 and full-year 2026.
The adjusted diluted EPS is projected to be within a favorable range.
Specific financial figures have been disclosed, enhancing transparency.
CONCERNS & RISKS
The impact of acquired IPR D and milestones expense is significant, reducing EPS.
Certain expenses beyond Q1 2026 cannot be reliably forecasted.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+33%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
paricalcitol
Phase 3 · Secondary Hyperparathyroidism
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended March 31, 2026
Full-Year Ended December 31, 2026
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q1 2026 acquired IPR D and milestones expense
$
-
$
2.97
$
3.01
$
-
$
14.37
$
14.57
Q1 2026 acquired IPR D and milestones expense
744
(0.41)
(0.41)
744
(0.41)
(0.41)
Guidance including Q1 2026 acquired IPR D and milestones expense a
$
744
$
2.56
$
2.60
$
744
$
13.96
$
14.16
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the first quarter of 2026, as both cannot be reliably forecasted.
Frequently Asked Questions
What was the Q1 2026 acquired IPR D expense?
The acquired IPR D and milestones expense for Q1 2026 was $744 million.
How does Q1 2026 impact the adjusted EPS range?
Including the Q1 2026 expense, the adjusted EPS range is $2.56 to $2.60.
What was the previously announced adjusted EPS range?
The previously announced adjusted EPS range was $2.97 to $3.01.
What is the full-year adjusted EPS guidance?
For the full year 2026, the adjusted EPS guidance is $13.96 to $14.16.
Does the 2026 guidance include future IPR D expenses?
The guidance excludes any future acquired IPR D expenses beyond Q1 2026.